Drug tolerant persisters in erlotinib treated EGFR-mutated lung adenocarcinoma arise from pre-existing tumor cells and survive in an adapted stromal microenvironment [RNA-seq]
Source: NCBI BioProject (ID PRJNA821227)
Source: NCBI BioProject (ID PRJNA821227)
0 0
Project name: Drug tolerant persisters in erlotinib treated EGFR-mutated lung adenocarcinoma arise from pre-existing tumor cells and survive in an adapted stromal microenvironment [RNA-seq]
Description: Targeted therapies require life-long treatment, as drug discontinuation invariably leads to tumor recurrence. Recurrence is thought to mainly be driven by minor subpopulations of drug tolerant persister (DTP) cells that survive the cytotoxic drug effect. In lung cancer, DTP studies have mainly been conducted using tumor cell line models.Overall design: single Cell RNAseq was performed on Baseline(BL) and DTP tumor
Data type: Transcriptome or Gene expression
Sample scope: Multiisolate
Relevance: Medical
Organization: Applied Molecular Oncology, Princess Margaret Cancer Research, University Health Network
Literatures
- PMID: 36535627
Last updated: 2022-03-29